Table 2.

MS-based, large-scale, quantitative proteomic studies utilizing models of prostate cancer.

Publication	Models Included	Specifications	References
Cima et al., 2011	Pten−/− mice	glycoproteomes of wt and Pten−/− prostates	[90]
Tan et al., 2014	VCaP cell line	proteomic changes with downregulation of ERG with siRNA; phosphoproteomics; in comparison with clinical samples	[60]
Jiang et al., 2015	LNCaP xenografts	phosphoproteomes in intact and castrated mice	[91]
Drake et al., 2016	cell lines and xenografts (22Rv1, LNCaP)	phosphoproteomics, integrative with genomic and transcriptomic data, in comparison with clinical tumor samples (see Table 1)	[55]
Höti et al., 2017	LNCaP, LNCaP-95	proteomic changes in androgen resistance	[92]
Zhang S. et al., 2018	cell lines PC-3M-2B4, PC-3M-1E8	proteomes associated with different metastatic ability	[93]
Zhang Y. et al., 2018	TRAMP mice	proteomes of wt and TRAMP prostates	[94]
Katsogiannou et al., 2019	cell lines PNT1A8, LNCaP, DU145, PC-3	differences in proteins and phosphosites between cell lines	[95]
Kwon et al., 2019	cell lines LNCaP, PC-3 LCaP-LN3, PC-3M	comparison of parental to more metastatic sub-lines	[96]
Miao et al., 2019	cell lines PC-3, PC-3MLN4	kinome associated with increased metastasis	[97]
Singh and Sharma, 2020	cell lines PC-3, LNCaP	proteomic changes in TGF-ß-induced EMT	[98]
Zhang et al., 2020	Pten−/− mice	proteomes of wt and Pten−/− prostates	[99]
Liynage et al., 2021	cell lines LNCaP, C4-2B	proteomic changes stimulated by anti-androgens bicalutamide and enzalutamide	[100]

BPH, benign prostatic hyperplasia; CRPC, castration-resistant prostate cancer; LNM, lymph node metastasis; MS, mass spectrometry; PCa, primary prostate cancer; WGS, whole genome sequencing.